Efficacy of Dengue Vaccines in the Prevention of Severe Dengue in Children: A Systematic Review.
dengue
dengue fever
dengue hemorrhagic fever
dengue infection
dengue shock syndrome
dengue tetravalent vaccine
dengue vaccination
dengue vaccine
dengvaxia
severe dengue
Journal
Cureus
ISSN: 2168-8184
Titre abrégé: Cureus
Pays: United States
ID NLM: 101596737
Informations de publication
Date de publication:
Sep 2022
Sep 2022
Historique:
received:
05
07
2022
accepted:
07
09
2022
entrez:
13
10
2022
pubmed:
14
10
2022
medline:
14
10
2022
Statut:
epublish
Résumé
Dengue is a vector-borne disease caused by the dengue virus (DENV) and is a major health concern worldwide, particularly in regions of endemic disease. Dengue usually presents as a self-limited febrile illness. In some cases, more severe forms with hemorrhage and shock can occur, and children are especially prone to develop it. These forms can be lethal without appropriate management, and no antiviral treatment exists today. In the absence of a curative treatment for dengue, its clinical prevention remains essential. One vaccine - the chimeric yellow fever-dengue-tetravalent dengue vaccine (CYD-TDV) - has been approved for use in some populations, and several others are currently in development, including Takeda's tetravalent dengue vaccine candidate (TAK-003). This study is a systematic review of the current literature realized to evaluate the efficacy of the dengue vaccines in preventing severe dengue in children. This review focuses on the vaccines CYD-TDV and TAK-003. This systematic review was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. PubMed, PubMed Central (PMC), Medical Literature Analysis and Retrieval System Online (MEDLINE), Cochrane Library, and Google Scholar were the databases used to find the relevant data. The articles were selected using specific inclusion and exclusion criteria, and quality appraisal was realized with standardized quality assessment tools. Overall, our study shows that the dengue vaccines CYD-TDV and TAK-003 confer protection against severe dengue in children. Some distinctions exist depending on the vaccine type, the age, and the dengue serostatus of patients. While demonstrating encouraging results, this review also emphasizes the need for more in-depth studies about the safety and efficacy of dengue vaccines.
Identifiants
pubmed: 36225478
doi: 10.7759/cureus.28916
pmc: PMC9542041
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
e28916Informations de copyright
Copyright © 2022, Foucambert et al.
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Lancet. 2014 Oct 11;384(9951):1358-65
pubmed: 25018116
Am J Forensic Med Pathol. 2016 Jun;37(2):74-8
pubmed: 27093563
Ther Adv Vaccines Immunother. 2021 May 17;9:25151355211015839
pubmed: 34036241
Plast Reconstr Surg. 2011 Jul;128(1):305-310
pubmed: 21701348
Hum Vaccin Immunother. 2019;15(10):2295-2314
pubmed: 31589551
Clin Lab Med. 2010 Mar;30(1):149-60
pubmed: 20513545
Clin Infect Dis. 2021 Sep 15;73(6):1003-1012
pubmed: 33822015
Science. 2017 Nov 17;358(6365):929-932
pubmed: 29097492
Vaccine. 2021 Aug 31;39(37):5318-5325
pubmed: 34373121
Can J Microbiol. 2021 Oct;67(10):687-702
pubmed: 34171205
Lancet. 2020 May 2;395(10234):1423-1433
pubmed: 32197105
Hum Vaccin Immunother. 2017 Sep 2;13(9):2004-2016
pubmed: 28598256
Expert Rev Anti Infect Ther. 2017 Jan;15(1):67-78
pubmed: 27786589
Vaccine. 2019 Aug 14;37(35):4848-4849
pubmed: 30424888
Vaccine. 2012 Sep 7;30(41):5935-41
pubmed: 22863660
Arch Virol. 2013 Jul;158(7):1445-59
pubmed: 23471635
N Engl J Med. 2019 Nov 21;381(21):2009-2019
pubmed: 31693803
BMJ. 2021 Mar 29;372:n71
pubmed: 33782057
N Engl J Med. 2015 Jan 8;372(2):113-23
pubmed: 25365753
Clin Microbiol Infect. 2018 Jul;24(7):755-763
pubmed: 29408333
Asian Pac J Allergy Immunol. 2020 Sep;38(3):178-185
pubmed: 30660171
Virol Sin. 2015 Oct;30(5):326-43
pubmed: 26494479
N Engl J Med. 2018 Jul 26;379(4):327-340
pubmed: 29897841
Lancet. 2020 May 2;395(10234):1434-1443
pubmed: 32197107
Expert Rev Vaccines. 2016;15(4):509-17
pubmed: 26559731
Lancet. 2012 Nov 3;380(9853):1559-67
pubmed: 22975340
J Immunol Res. 2016;2016:6803098
pubmed: 27525287